Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease

Pharmacogenetics and Genomics

Volumn 18, Issue 11, 2008, Pages 943-953

  Smith, Helen E ^a   Jones III, J P ^a   Kalhorn, Thomas F ^a   Farin, Federico M ^a   Stapleton, Patricia L ^a   Davis, Connie L ^b   Perkins, James D ^b   Blough, David K ^a   Hebert, Mary F ^a   Thummel, Kenneth E ^a   Totah, Rheem A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Arachidonic acid; Calcineurin inhibitor; Cyclosporine A; CYP2C8; CYP2J2; Liver transplantation; Nephrotoxicity; Polymorphism; Tacrolimus

Indexed keywords

ARACHIDONIC ACID; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; CYTOCHROME P450 2C8; CYTOCHROME P450 2J2; EPOXYICOSATRIENOIC ACID; GENE PRODUCT; TACROLIMUS;

ALLELE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG INHIBITION; ENZYME POLYMORPHISM; EPOXIDATION; ESCHERICHIA COLI; FEMALE; GENOTYPE; HAPLOTYPE; HYPERGLYCEMIA; HYPERTENSION; IN VITRO STUDY; INHERITANCE; KIDNEY; KIDNEY DYSFUNCTION; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; RISK; WILD TYPE;

8,11,14-EICOSATRIENOIC ACID; ARACHIDONIC ACID; ARYL HYDROCARBON HYDROXYLASES; CALCINEURIN; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DEMOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; KINETICS; MALE; MIDDLE AGED; TACROLIMUS; UNITED STATES;

EID: 56149085504     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32830e1e16     Document Type: Article

References (40)

1. Hamawy MM. Molecular actions of calcineurin inhibitors. Drug News Perspect 2003; 16:277-282.
2. Lucey MR, Abdelmalek MF, Gagliardi R, Granger D, Holt C, Kam I, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005; 5:1111-1119.
3. Healy E, Dempsey M, Lally C, Ryan MP. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 1998; 54:1955-1966.
4. Neuberger J. Liver transplantation. J Hepatol 2000; 32:198-207.
5. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71:1282-1287.
6. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
7. Stratta P, Canavese C, Quaglia M, Balzola F, Bobbio M, Busca A, et al. Posttransplantation chronic renal damage in nonrenal transplant recipients. Kidney Int 2005; 68:1453-1463.
8. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7:384-389.
9. Gallon L, Akalin E, Lynch P, Rothberg L, Parker M, Schiano, et al. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. Transplantation 2006; 81:463-468.
10. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16:1501-1511.
11. Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13:661-674.
12. Imig JD. Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol 2000; 279:F965-F981.
13. Mallat Z, Nakamura T, Ohan J, Leseche G, Tedgui A, Maclouf J, Murphy RC. The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 1999; 103:421-427.
14. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285:1276-1279.
15. Rifkind AB, Lee C, Chang TK, Waxman DJ. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 1995; 320:380-389.
16. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-185.
17. Dos Santos EA, Dahly-Vernon AJ, Hoagland KM, Roman RJ. Inhibition of the formation of EETs and 20-HETE with 1-aminobenzotriazole attenuates pressure natriuresis. Am J Physiol Regul Integr Comp Physiol 2004; 287:R58-R68.
18. Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, et al. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 2003; 42:594-599.
19. Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, Kroetz DL. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol 2000; 57:1011-1020.
20. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004; 110:2132-2136.
21. Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD, Wu S. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 1996; 330:87-96.
22. Rodriguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, Ingelman-Sundberg M. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J 2008; 4:266-267.
23. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004; 10:301-309.
24. Guryev OL, Gilep AA, Usanov SA, Estabrook RW. Interaction of apocytochrome b5 with cytochromes P4503A4 and P45017A: relevance of heme transfer reactions. Biochemistry 2001; 40:5018-5031.
25. Barnes HJ, Arlotto MP, Waterman MR. Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA 1991; 88:5597-5601.
26. Cheesman MJ, Baer BR, Zheng YM, Gillam EM, Rettie AE. Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group. Arch Biochem Biophys 2003; 416:17-24.
27. McGuire BB, Watson RW, Perez-Barriocanal F, Fitzpatrick JM, Docherty NG. Gender differences in the renin-angiotensin and nitric oxide systems: relevance in the normal and diseased kidney. Kidney Blood Press Res 2007; 30:67-80.
28. Munikrishnappa D. Chronic kidney disease (CKD) in the elderly - a geriatrician's perspective. Aging Male 2007; 10:113-137.
29. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004; 52:447-454.
30. Dai D, Zeldin DC, Blaisdell JA, Ghanas B, Coulter SJ, Ghanayem BI, Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607.
31. Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999; 65:251-261.
32. Meerum Terwogt JM, Malingre MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman F, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999; 5:3379-3384.
33. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005; 78:388-399.
34. Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77:341-352.
35. Renders L, Haas CS, Liebelt J, Oberbarnscheidt M, Schocklmann HO, Kunzendorf U. Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. Br J Clin Pharmacol 2003; 56:214-219.
36. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000; 87:992-998.
37. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004; 15:1244-1253.
38. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002; 299:25-28.
39. Backman JT, Kajosaari LI, Niemi M, Neuvonen PJ. Cyclosporine A increases plasma concentrations and effects of repaglinide. Am J Transplant 2006; 6:2221-2222.
40. Gil J, Gil Berglund E. CYP2C8 and antimalaria drug efficacy. Pharmacogenomics 2007; 8:187-198.